Determining Treatment Options for Select Subsets of Neuroendocrine Tumors

Video
Conference|ISGIO Annual Conference

Thor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.

Thor Halfdanarson, MD, medical oncologist at Mayo Clinic, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.

Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Updated Zanidatamab Data Shows Durable Response in Biliary Tract Cancer

Updated Zanidatamab Data Shows Durable Response in Biliary Tract Cancer

Jordyn Sava
November 23rd 2024
Article

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

Nichole Tucker;Benjamin L. Schlechter, MD
February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Sabrina Serani
November 6th 2024
Article

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

Read More